Journal of Pharma Creations (JPC)

JPC |Vol.12 | Issue 3 | Jul - Sept -2025

www.pharmacreations.com

DOI : https://doi.org/10.61096/jpc.v12.iss3.2025.174-176

ISSN: 2348-6295

Review

An Overview of Latam Regulatory Requirements for Pharmaceutical Product Development

SingamVaralaxmi[1], S. Rohini Reddy[2], Swetha. M[*3]

[1]M.Pharm Student, Department of Regulatory Affairs, Sarojini Naidu Vanita Pharmacy Maha Vidyalaya, Telangana, India. Affiliated to Osmania University.
[2]Associate Professor, Department of Regulatory Affairs, Sarojini Naidu Vanita Pharmacy Maha Vidyalaya, Telangana, India. Affiliated to Osmania University.
[3]Associate Professor & Head, Department of Regulatory Affairs, Sarojini Naidu Vanita Pharmacy Maha Vidyalaya, Telangana, India. Affiliated to Osmania University.

[*]Author for Correspondence: Dr. M. Swetha
Email: swethasnvpm@gmail.com

Published on: 27 Sept 2025

Published by:
Futuristic Publications

Abstract

The Latin American (LATAM) pharmaceutical market is growing rapidly, driven by increasing demand for innovative medicines, biologics, and generics. However, the diversity of regulatory frameworks among LATAM countries presents significant challenges for pharmaceutical companies. This review summarizes the regulatory landscape of major LATAM nations, focusing on their respective health authorities, approval processes, and documentation requirements. A comparative table is provided to assist stakeholders in navigating the complexities of the region's regulatory systems.

Keywords: LATAM, Regulatory Affairs, ANVISA, COFEPRIS, INVIMA, Pharmaceuticals, Drug Approval

1. INTRODUCTION

Latin America (LATAM) comprises over 20 countries, each with its own regulatory authority and pharmaceutical approval process. While some countries, like Brazil and Mexico, have highly developed regulatory systems recognized by the World Health Organization (WHO) as stringent authorities, others follow less formalized procedures. For pharmaceutical product development, understanding the variations in submission requirements, review timelines, and clinical trial regulations is crucial for successful market entry.

2. Regulatory Framework in LATAM

2.1 Importance of Regulatory Harmonization

Harmonization across LATAM remains limited, although initiatives such as the Pan American Network for Drug Regulatory Harmonization (PANDRH) and reliance on EMA/FDA approvals are gaining traction.

2.2 Common Challenges

- Lack of unified submission platform across LATAM
- Differences in GMP inspection requirements
- Variations in dossier format (CTD vs. non-CTD)
- Inconsistent approval timelinesVERVIEW OF LATAM REGULA

3. Country-wise Regulatory Overview

Country	Regulatory Authority	Dossier Format	Average Approval Timeline	Key Notes
Brazil	ANVISA (Agência Nacional de VigilânciaSanitária)	eCTD / CTD	12–18 months	WHO Listed Authority; mandatory GMP inspection
Mexico	COFEPRIS (Comisión Federal para la Protección contra RiesgosSanitarios)	CTD	8–12 months	Accepts reliance on FDA/EMA approvals
Argentina	ANMAT (Administración Nacional de Medicamentos, Alimentos y TecnologíaMédica)	CTD	12–16 months	Follows MERCOSUR guidelines
Colombia	INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos)	CTD	6–12 months	Participates in PAHO regulatory strengthening
Chile	ISP (Instituto de SaludPública)	CTD	8–10 months	Fast-track for essential medicines
Peru	DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)	CTD	8–14 months	Follows Andean Community agreements
Ecuador	ARCSA (Agencia Nacional de Regulación, Control y Vigilancia Sanitaria)	CTD	10–14 months	Relies on regional approvals
Uruguay	MSP (Ministerio de SaludPública)	CTD	12–15 months	MERCOSUR member; small market but regulated
Paraguay	DNVS (Dirección Nacional de Vigilancia Sanitaria)	CTD	10–14 months	MERCOSUR harmonization efforts

4. DISCUSSIONS

The LATAM region demonstrates a spectrum of regulatory maturity. Countries like Brazil, Mexico, and Colombia have developed regulatory authorities capable of independent evaluation, while others rely heavily on reference country approvals. Pharmaceutical companies must adopt a tailored strategy, often leveraging reliance pathways to reduce time-to-market.

Recent trends include:

- Implementation of electronic submissions (Brazil, Mexico, Colombia)
- Increased participation in WHO Listed Authority programs
- Regional collaboration through MERCOSUR and the Andean Community

5. CONCLUSION

The LATAM pharmaceutical regulatory environment offers significant opportunities but requires careful navigation due to diverse requirements and timelines. Early engagement with local regulatory experts, use of reliance procedures, and proactive GMP compliance are key to successful product registration.

6. REFERENCES

1. Pan American Health Organization (PAHO). *PANDRH: Regulatory Harmonization in the Americas*. 2023.
2. ANVISA. *Medicamentos e Produtos para Saúde: Procedimentos de Registro*. 2024.
3. COFEPRIS. *Guía de RegistroSanitario de Medicamentos*. 2023.
4. INVIMA. *ReglamentoTécnico para el RegistroSanitario*. 2024.
5. ANMAT. *Normativas para ProductosFarmacéuticos*. 2023.
6. DIGEMID. *Guía de Presentación de Expedientes*. 2023.
7. ISP Chile. *Procedimiento de RegistroSanitario de Medicamentos*. 2024.
8. ARCSA. *Reglamento de Medicamentos y ProductosBiológicos*. 2023.
9. World Health Organization. *Global Benchmarking of Regulatory Systems*. 2024.